Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
alzheimer save search
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
DGX | News | $136.7 5.08% 0.0% 2.1M
|
Health Services
|
| O: 0.33%
H: 0.0%
C: 0.0%
disease services biomarker blood risk alzheimer's diagnostics
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
NRSN | News | $1.35 -6.77% 79K
|
|
| O: -1.41%
H: 2.86%
C: -3.57%
precision disease ongoing alzheimer's collaboration trial
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CGTX | News | $2.02 8.6% 7.92% 140K
|
|
| O: -2.17%
H: 7.78%
C: 3.33%
disease alzheimer’s treat for therapeutics platform
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Published: 2024-04-17 (Crawled : 16:00) - biospace.com/
HYPR | $0.849 -0.12% -0.12% 130K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -8.08%
first alzheimer’s care enroll therapy study
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN 4 d | $1.79 -4.28% -4.47% 270K
|
|
| O: 41.42%
H: 42.68%
C: 22.59%
conference disease association alzheimer’s presentation international research for trial
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.035 -2.63% -2.7% 85K
|
Health Technology
|
| O: 4.9%
H: 6.03%
C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.8 -9.55% -10.56% 5.2M
|
Finance and Insurance
|
| O: 1.87%
H: 4.59%
C: -3.67%
pharma disease alzheimer’s acquire spc-14
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
BTAI | News | $2.965 4.04% 3.88% 410K
|
Health Technology
|
| O: 0.96%
H: 1.9%
C: 0.0%
bxcl501 alzheimer’s dementia for trial therapeutics
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
ABOS | $3.15 0.64% 0.63% 270K
|
Professional, Scientific, and T...
|
| O: 4.19%
H: 2.01%
C: -3.52%
disease alzheimer’s treatment pharmaceuticals
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
CGTX | News | $2.02 8.6% 7.92% 140K
|
|
| O: 1.67%
H: 0.0%
C: 0.0%
disease alzheimer’s therapeutics
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
leqembi fda disease license treatment alzheimer's application submission
Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
DGX | News | $136.7 5.08% 0.0% 2.1M
|
Health Services
|
| O: 0.26%
H: 0.1%
C: -0.58%
disease test blood alzheimer's imaging study
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
ANVS | $11.88 3.39% 0.0% 230K
|
Health Technology
|
| O: 10.43%
H: 34.62%
C: 12.69%
announcement disease alzheimer’s update buntanetap study
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials
Published: 2024-03-20 (Crawled : 11:00) - prnewswire.com
LH M | $207.97 2.41% 0.0% 930K
|
Health Services
|
| O: -0.32%
H: 0.29%
C: -0.45%
disease test biomarker blood trials alzheimer's
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Published: 2024-03-19 (Crawled : 15:30) - biospace.com/
HOTH | $1.15 1.2% 29K
|
Health Technology
|
| O: 21.74%
H: 19.29%
C: -3.57%
disease pre-clinical positive treatment alzheimer's therapeutics ht-alz study
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
Published: 2024-03-08 (Crawled : 14:00) - globenewswire.com
ABOS | $3.15 0.64% 0.63% 270K
|
Professional, Scientific, and T...
|
| O: 2.06%
H: 0.0%
C: 0.0%
acu193 biomarker alzheimer’s pharmaceuticals meeting study
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
ATHA | $2.035 -2.63% -2.7% 85K
|
Health Technology
|
| O: 0.0%
H: 1.45%
C: -13.73%
fosgonimeton pharma conference alzheimer’s international preclinical parkinson’s potential
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Published: 2024-03-07 (Crawled : 13:30) - globenewswire.com
IKT | $1.57 14.6% 12.74% 78K
|
Health Technology
|
| O: 0.41%
H: 2.89%
C: 0.0%
conference alzheimer’s update international disorders neurological parkinson’s trial therapeutics
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
CGTX | News | $2.02 8.6% 7.92% 140K
|
|
| O: -1.9%
H: 1.94%
C: -0.97%
ct1812 disease alzheimer’s treatment therapeutics
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.